TY - JOUR
T1 - Treatment outcomes and adverse events from a standardized multidrug-resistant tuberculosis regimen in a rural setting in Angola
AU - Aznar, María Luisa
AU - Segura, Ariadna Rando
AU - Moreno, María Milagros
AU - Espasa, Mateu
AU - Sulleiro, Elena
AU - Bocanegra, Cristina
AU - Olivas, Eva Gil
AU - Eugénio, Arlete Nindia
AU - Zacarias, Adriano
AU - Katimba, Domingos
AU - Gabriel, Estevao
AU - Mendioroz, Jacobo
AU - García, Maria Teresa López
AU - Pumarola, Tomas
AU - Tórtola, María Teresa
AU - Molina, Israel
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Copyright © 2019 by The American Society of Tropical Medicine and Hygiene. Treatment for multidrug-resistant tuberculosis (MDR TB) is associated with adverse events (AE). Patients treated with an MDR TB regimen in Hospital Nossa Senhora da Paz, Cubal, Angola, were prospectively enrolled from May 2013 to July 2015. Baseline characteristics, AE, and clinical and microbiological outcomes were recorded. A total of 216 patients were treated with an MDR TB regimen and 179 (82.9%) patients developed at least one AE. The most common AE were elevation of liver enzymes (46.8% of patients), elevated creatinine (44.4% of patients), and ototoxicity (40.7% of patients). Previous TB treatment was associated with the occurrence of AE (OR 4.89, 95% CI: 2.09–11.46, P < 0.001) and months on treatment was associated to severe AE (OR 1.11 95% CI: 1.04–1.18, P = 0.001). Successful treatment was achieved in 117 (54.2%) patients. Incidence of AE was associated with an unsuccessful outcome (OR 1.23, 95% CI: 1.09–1.40, P = 0.001). Patients treated with MDR TB treatment frequently experience AE, and these are related with previous TB treatment and duration of treatment. Given the high percentage of patients experiencing AE and the low treatment success rates, more effective and less toxic drugs to treat MDR TB are urgently needed.
AB - Copyright © 2019 by The American Society of Tropical Medicine and Hygiene. Treatment for multidrug-resistant tuberculosis (MDR TB) is associated with adverse events (AE). Patients treated with an MDR TB regimen in Hospital Nossa Senhora da Paz, Cubal, Angola, were prospectively enrolled from May 2013 to July 2015. Baseline characteristics, AE, and clinical and microbiological outcomes were recorded. A total of 216 patients were treated with an MDR TB regimen and 179 (82.9%) patients developed at least one AE. The most common AE were elevation of liver enzymes (46.8% of patients), elevated creatinine (44.4% of patients), and ototoxicity (40.7% of patients). Previous TB treatment was associated with the occurrence of AE (OR 4.89, 95% CI: 2.09–11.46, P < 0.001) and months on treatment was associated to severe AE (OR 1.11 95% CI: 1.04–1.18, P = 0.001). Successful treatment was achieved in 117 (54.2%) patients. Incidence of AE was associated with an unsuccessful outcome (OR 1.23, 95% CI: 1.09–1.40, P = 0.001). Patients treated with MDR TB treatment frequently experience AE, and these are related with previous TB treatment and duration of treatment. Given the high percentage of patients experiencing AE and the low treatment success rates, more effective and less toxic drugs to treat MDR TB are urgently needed.
U2 - 10.4269/ajtmh.19-0175
DO - 10.4269/ajtmh.19-0175
M3 - Article
C2 - 31333153
VL - 101
SP - 502
EP - 509
ER -